US OptionsDetailed Quotes
BIVI250117C7500
- 0.10
- 0.000.00%
15min DelayTrading Aug 5 16:00 ET
0.00High0.00Low
0.00Open0.10Pre Close0 Volume44 Open Interest7.50Strike Price0.00Turnover179.38%IV155.03%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier46DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.1334Delta0.1126Gamma29.80Leverage Ratio-0.0045Theta0.0004Rho3.98Eff Leverage0.0023Vega
BioVie Stock Discussion
BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference
BioVie (NASDAQ: BIVI) announced the acceptance of an abstract detailing their planned Phase 2 trial of bezisterim for Long COVID treatment at the Demystifying Long COVID International Conference in Barcelona. The study, fully funded by the U.S. Department of Defense, will be a double-blind, randomized, placebo-controlled tri...
📊⚡️📊
Biovie’s Upcoming Parkinson’s Disease Clinical Trial Is Fully Funded
BioVie Inc. Announces Pricing of Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
BioVie Inc (NASDAQ: BIVI) announced the pricing of a registered direct offering of 1,146,000 shares of common stock at $2.83 per share, aiming to raise approximately $3.2 million in gross proceeds. The offering, priced at-the-market under Nasdaq rules, is expected to close around October 29, 2024. The company plans to use the net proceeds for working capital and general corpo...
No comment yet